Sign in

    Jack Christopher Siedow • Craig-Hallum Capital Group LLC

    Jack Christopher Siedow is an Equity Research Associate at Craig-Hallum Capital Group LLC, specializing in coverage of healthcare and biotechnology companies such as Champions Oncology. Siedow has demonstrated expertise in providing in-depth analysis for equities within the biotech sector and supports Craig-Hallum’s research team with actionable insights, as evidenced by his active participation in public earnings calls. He began his financial career prior to 2022, gained experience at RBC Capital Markets and Needham & Company, and joined Craig-Hallum in 2024. Siedow maintains active professional credentials, including FINRA registration and securities licenses through prior roles at registered broker-dealers.

    Jack Christopher Siedow's questions to Champions Oncology Inc (CSBR) leadership

    Jack Christopher Siedow's questions to Champions Oncology Inc (CSBR) leadership • Q2 2025

    Question

    Jack Christopher Siedow, on behalf of Matt Hewitt from Craig-Hallum Capital Group LLC, inquired about the current market dynamics and funding environment for biotech, and also asked about potential new services or tests that could drive future growth.

    Answer

    CEO Ronnie Morris stated that while the funding environment has not fully returned to levels from a few years ago, it has improved over the last year, and the company is cautiously optimistic. Regarding growth, Morris emphasized the significant value of the company's deep multiomic data set, which is becoming more valuable with the advent of AI. He announced that Champions Oncology expects to introduce a new data licensing revenue stream in the coming quarter, which he believes will be transformative for the company's revenue and margins, in addition to the continued strength of its core in-vivo and ex-vivo study services.

    Ask Fintool Equity Research AI